Teva’s laquinimod hints at efficacy in Crohn’s
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries’ investigational product for multiple sclerosis, laquinimod, has shown some potential in a Phase II trial in one of its follow-on indications, Crohn’s disease.